Jose Garcia Mateo, MD
Endocrinology, Diabetes & Metabolism · Ponce, PRNPI 1932275484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $771,846 of the $944,576 with a category attached, or 81.7%. 34 manufacturers reported payments, led by Lilly USA, LLC at 27.2% of the total. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,620 payments — averaging $583.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$257K
- AstraZeneca$164K
- Boehringer Ingelheim$114K
- Bayer$101K
- Amgen$93K
- Sanofi-aventis U.S. LLC$66K
- plus $150K from 28 others
What the payments were for
- Consulting fees$31,1073%
- Speaking & faculty fees$771,84682%
- Travel & lodging$94,60710%
- Food & beverage$46,9255%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 395 | $256,840 |
| AstraZeneca | 238 | $164,350 |
| Boehringer Ingelheim | 174 | $113,873 |
| Bayer | 125 | $101,350 |
| Amgen | 134 | $92,608 |
| Sanofi-aventis U.S. LLC | 122 | $66,005 |
| Johnson & Johnson | 70 | $49,927 |
| Madrigal Pharmaceuticals | 70 | $42,024 |
| Corcept Therapeutics | 46 | $27,461 |
| Eli Lilly Export S.A. Puerto Rico Branch | 68 | $18,244 |
| Medicure Pharma Inc. | 3 | $4,500 |
| AbbVie | 22 | $2,993 |
| Abbott | 29 | $667 |
| Novo Nordisk | 23 | $477 |
| Medtronic | 3 | $426 |
| Merck | 22 | $418 |
| Bayer Puerto Rico Inc. | 39 | $363 |
| Ascendis Pharma Endocrinology Inc | 2 | $278 |
| Radius Health, Inc. | 6 | $230 |
| PBG Puerto Rico LLC | 9 | $172 |
| Novartis | 3 | $156 |
| Edwards Lifesciences | 2 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $148 |
| Vifor Pharma, Inc. | 2 | $137 |
| Scpharmaceuticals Inc. | 1 | $125 |
| Perspectum Diagnostics Ltd | 1 | $117 |
| Dexcom, Inc. | 2 | $112 |
| Kyowa Kirin, Inc. | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $81 |
| Pfizer | 1 | $73 |
| Boston Scientific | 1 | $69 |
| GSK | 1 | $51 |
| Ionis Pharmaceuticals, Inc. | 1 | $33 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$159,515
- JARDIANCE$159,217
- MOUNJARO$154,569
- Kerendia$99,358
- Repatha$88,959
- INVOKANA$40,684
- REZDIFFRA$40,175
- SOLIQUA 100/33$35,758
- Korlym$26,549
- HUMULIN$26,400
- TOUJEO$22,797
- TRULICITY$16,516
- XARELTO$7,649
- PRALUENT$3,649
- ZYPITAMAG (pitavastatin)$3,000
- Synthroid$2,495
- Aggrastat (tirofiban HCl)$1,500
- TZIELD$819
- EVENITY$618
- TEPEZZA$550
How this compares
$944,576 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 1,160 | $1,160,626 |
| KorlymMifepristone | 12 | $587,586 |
| FarxigaDapagliflozin Propanediol | 869 | $567,714 |
| OzempicSemaglutide | 557 | $552,006 |
| JardianceEmpagliflozin | 672 | $469,769 |
| MounjaroTirzepatide | 345 | $371,773 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 378 | $249,542 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 262 | $235,638 |
| KerendiaFinerenone | 314 | $232,267 |
| Repatha SureclickEvolocumab | 297 | $169,059 |
| ForteoTeriparatide | 33 | $144,772 |
| SynthroidLevothyroxine Sodium | 2,374 | $144,671 |
| JanumetSitagliptin Phos/Metformin Hcl | 150 | $103,783 |
| JanuviaSitagliptin Phosphate | 142 | $100,672 |
| TymlosAbaloparatide | 36 | $96,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $256,840 | $1,697,9471,674 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Glyxambi | $113,873 | $986,2491,467 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $164,350 | $620,984959 claims |
| Corcept TherapeuticsKorlym | $27,461 | $587,58612 claims |
| Novo NordiskOzempic | $477 | $552,006557 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $66,005 | $307,097955 claims |
| MerckJanumet, Januvia, Janumet Xr | $418 | $252,443367 claims |
| BayerKerendia | $101,350 | $232,267314 claims |
| AbbVieSynthroid | $2,993 | $144,6712,374 claims |
| AmgenProlia, Evenity (2 Syringes) | $92,608 | $136,88268 claims |
| Radius Health, Inc.Tymlos | $230 | $96,31336 claims |
| Johnson & JohnsonXarelto, Invokana | $49,927 | $81,017115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Ponce
- Cesar TrabancoPonce$20K
- Alejandra SantiagoPonce$11K
- Alegyari Figueroa CruzPonce$10K
- Andres Ortiz NievesPonce$8K
- Laurianne El Musa PennaPonce$7K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.